How do you envision the role of AI evolving in the drug discovery process over the next decade? Colin Brown: “The role of AI in the discovery…
Read update 24th September, 2024What are the latest trends for new in vitro models? There are really two trends. The first one, of course, is to make more physiologically…
Read update 20th September, 2024What are the latest trends for new in vitro models? In the field, we have been talking about very complex models, so-called organs on chip,…
Read update 28th August, 2024What are the latest trends for new in vitro models ? I think the latest trend that we are seeing is in terms of the ability of…
Read update 11th June, 2024Dr Valeria Chichagova appointed as Director of Technology, Dr Colin Brown as Chief Scientific Officer, and Professor Lyle Armstrong as Scientific Advisor New US commercial appointments also announced…
Read update 29th August, 2023CAR-T Therapy CAR-T Therapy is a form of immunotherapy that harnesses the power of the patient’s immune system to target and eliminate cancer cells. It involves ex-vivo genetic engineering of…
Read updateNewcells Biotech (“Newcells”), a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes,…
Read update 12th July, 2024A Unique Exhibition-Poster Integration One striking feature of JSOT is how they seamlessly integrate exhibitions with poster sessions. Exhibitors and poster presenters are…
Read update 8th July, 2024Newcells Biotech (“Newcells”), a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes,…
Read update 28th June, 2024How does Newcells works with their clients? Listen to our CEO, Dr Mike Nicholds explaining. Webinar on demand: Moving compounds to IND using predictive retinal models. Our panel of experts…
Read update 11th June, 2024Dr Valeria Chichagova appointed as Director of Technology, Dr Colin Brown as Chief Scientific Officer, and Professor Lyle Armstrong as Scientific Advisor New US commercial appointments also announced…
Read update 6th March, 2024The Newcastle-based company has secured funding from existing investors including the North East Venture Fund, supported by the European Regional Development Fund and managed by Mercia Ventures, Mercia’s own funds…
Read update